ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
26 announcements with these filters
Suraksha Diagnostic Ltd held its 21st AGM on September 22, 2026. Members adopted financial statements, approved a final dividend, and ratified cost auditor remuneration.
Suraksha Diagnostic Limited has issued a notice for its 21st Annual General Meeting scheduled for September 22, 2026, to conduct routine business and dividend declaration.
Suraksha Diagnostic Limited has issued a notice for its 21st Annual General Meeting to be held on September 22, 2026, to transact key corporate business.
Suraksha Diagnostic informed exchanges about dispatching letters to shareholders with unregistered emails, providing web links to access the 21st AGM notice and Annual Report.
Suraksha Diagnostic Limited has filed its Annual Report for FY 2025-26, including the notice for the 21st Annual General Meeting scheduled for September 22, 2026.
Suraksha Diagnostic reported a robust Q1 FY27 with 21% revenue growth and 40% PAT growth, driven by expansion in West Bengal and Jharkhand and a high-growth genomics segment.
Suraksha Diagnostic reported strong Q1 FY27 results with 21% YoY revenue growth and 14.7% PAT margin. Management is aggressively expanding the hub-and-spoke network beyond West Bengal into Jharkhand and Tripura.
Suraksha Diagnostic reported Q1 FY27 results with total income of ₹88.73 Crore and PAT of ₹12.85 Crore, reflecting 21% and 40% year-on-year growth respectively.
Suraksha Diagnostic Limited has appointed Mr. Dinesh Gupta as the Chief Financial Officer (CFO), effective August 24, 2026. This key leadership appointment aims to strengthen the company's financial management.
Suraksha Diagnostic Limited declared a final dividend of Rs 0.50 per share for FY 2025-26. The record date for the dividend is September 15, 2026.
Suraksha Diagnostic Ltd reported revenue from operations of ₹87.6 Cr (+20.7% YoY) and net profit of ₹12.8 Cr (+39.1% YoY) for Q1 FY27.
Suraksha Diagnostic Limited has postponed its 21st Annual General Meeting, originally scheduled for September 2, 2026. The company will announce the revised date and venue later.
Suraksha Diagnostic Limited has scheduled a board meeting for August 12, 2026, to consider and approve its unaudited standalone and consolidated financial results.
Suraksha Diagnostic Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The report outlines the distribution of shares among promoters and public shareholders.
Ms. Mamta Jain resigned as Company Secretary and Compliance Officer effective July 15, 2026. The resignation is for personal reasons and carries no other material impact.
Suraksha Diagnostic Limited concluded FY26 with 23.1% revenue growth to INR 3104M. Strategy shifts towards specialized genomics and multi-state expansion into Bihar, Tripura, and Jharkhand.
Suraksha Diagnostic Limited submitted its Annual Secretarial Compliance Report for FY 2025-26. The report confirms overall regulatory adherence with no material non-compliances noted by the secretary.
Suraksha Diagnostic reported robust FY26 revenue growth of 23.1% YoY, driven by aggressive regional expansion and a shift toward high-value genomic and specialized radiology testing.
Suraksha Diagnostic reported FY26 total income of ₹313.58 Crore, up 22.5% year-on-year. EBITDA reached ₹98.56 Crore as the company expanded its regional diagnostic footprint.
Suraksha Diagnostic reported robust FY26 results with 23% revenue growth and 16% EBITDA growth, driven by core diagnostic momentum and expansion in Eastern India.
Suraksha Diagnostic recommended a final dividend of ₹0.50 per equity share for FY26. The record date for payment eligibility is set for August 26, 2026.
Suraksha Diagnostic Limited appointed Suresh Surana & Associates LLP as Internal Auditor and re-appointed S Chhaparia & Associates as Cost Auditor. Both appointments are for 12 months.
Suraksha Diagnostic Ltd reported revenue from operations of ₹81.4 Cr (+25.0% YoY) and net profit of ₹6.2 Cr (-13.9% YoY) for Q4 FY26.
Suraksha Diagnostic Limited approved its FY2025-26 audited financial results and recommended a ₹0.50 dividend. The board also appointed new internal and cost auditors for FY2026-27.
Suraksha Diagnostic will hold a board meeting on May 21, 2026, to consider audited yearly results and final dividend. Trading window remains closed until May 23.
Suraksha Diagnostic Limited submitted its quarterly certificate under SEBI Regulation 74(5) for the period ended March 31, 2026. The registrar, KFin Technologies, confirmed that no shares were received for dematerialization or rematerialization during the quarter.